IPCI - IntelliPharmaCeutics International Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

IntelliPharmaCeutics International Inc.

30 Worcester Road
Toronto, ON M9W 5X2

IndustryDrug Delivery
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Isa Odidi Ph.D., MBACo-Founder, Chairman, CEO & Co-Chief Scientist694.49kN/A1958
Dr. Amina Odidi Ph.D.Pres, Chief Operating Officer, Co-Chief Scientific Officer and Director694.49kN/A1960
Mr. Andrew P. Patient B.Acc, C.A.Chief Financial OfficerN/AN/A1971
Dr. Patrick N. Yat Ph.D.VP of Pharmaceutical Analysis & ChemistryN/AN/A1958
Mr. Christian AkyemponVP of Commercial OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


IntelliPharmaCeutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Oxycodone ER, an abuse deterrent oxycodone hydrochloride extended release tablets; Regabatin and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease; and Glucophage XR, a drug that treats type 2 diabetes. It also provides Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company provides Focalin XR, an extended-release capsule for hyperactivity disorder. It has has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Corporate Governance

IntelliPharmaCeutics International Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.